Magnasense AB Company Description

Magnasense AB develops and commercializes diagnostic tests for monitoring and optimizing the dosage of biological drugs in Sweden and internationally.

The company develops a home testing platform for oral health, therapeutic drug monitoring, and infectious diseases.

Its product line includes the Veritope technology with intact natalizumab in multiple sclerosis; and the MagniaReader which is utilized in research and veterinary applications.

The company was formerly known as AegirBio AB (publ) and changed its name to Magnasense AB in July 2024.

Magnasense AB was incorporated in 2019 and is headquartered in Lund, Sweden.

Magnasense AB

Country	Sweden
Founded	2019
Industry	Medical Devices
Sector	Healthcare
Employees	14
CEO	Marco Witteveen

Contact Details

Address: Scheelevägen 27 Lund, 223 63 Sweden
Phone	46 4 62 86 54 00
Website	magnasense.com

Stock Details

Ticker Symbol	MAGNA
Exchange	Nasdaq Stockholm
Fiscal Year	January - December
Reporting Currency	SEK
SIC Code	2835

Key Executives

Name	Position
Marco Witteveen	Chief Executive Officer and Director
Vicki Johnson	Interim Chief Financial Officer
Dr. Vasiliki Fragkou	Chief Operating Officer